You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR APREMILAST

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for apremilast

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00456092 ↗	Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis	Completed	Amgen	Phase 2	2007-03-05	This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
NCT00456092 ↗	Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis	Completed	Celgene Corporation	Phase 2	2007-03-05	This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
NCT00521339 ↗	Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis	Completed	Amgen	Phase 2	2007-08-01	The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00521339 ↗	Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis	Completed	Celgene Corporation	Phase 2	2007-08-01	The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00604682 ↗	Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis	Completed	Amgen	Phase 2	2005-01-01	Open label study for patients with severe plaque type psoriasis. This study is looking to evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the epidermal thickness in subjects with severe placque type psoriasis.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for apremilast

Condition Name

Chart
Table

Condition Name for apremilast
Intervention	Trials
Psoriasis	24
Psoriatic Arthritis	15
Plaque Psoriasis	13
Healthy Volunteers	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for apremilast
Intervention	Trials
Psoriasis	48
Arthritis, Psoriatic	20
Arthritis	20
Dermatitis	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for apremilast

Trials by Country

Map
Table

Trials by Country for apremilast
Location	Trials
United States	598
Canada	135
Japan	59
Australia	38
Germany	35
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for apremilast
Location	Trials
California	38
Florida	36
Texas	33
New York	32
Illinois	24
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for apremilast

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for apremilast
Clinical Trial Phase	Trials
Phase 4	23
Phase 3	35
Phase 2	39
[disabled in preview]	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for apremilast
Clinical Trial Phase	Trials
Completed	62
Recruiting	20
Active, not recruiting	7
[disabled in preview]	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for apremilast

Sponsor Name

Chart
Table

Sponsor Name for apremilast
Sponsor	Trials
Amgen	53
Celgene Corporation	50
Celgene	22
[disabled in preview]	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for apremilast
Sponsor	Trials
Industry	136
Other	94
NIH	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.